Clinical Trial Update: Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTI [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is evaluating body weight and BMI changes in people with HIV treated with DOR/3TC/TDF compared to an INSTI regimen; the study is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• DOR/3TC/TDF (doravirine/lamivudine/tenofovir disoproxil fumarate) (doravirine/lamivudine/tenofovir disoproxil fumarate)
• Integrase inhibitor (INSTI) class (integrase strand transfer inhibitor)

Snippet

Sponsor: Instituto Mexicano del Seguro Social | Conditions: HIV, HIV Associate Weight Loss | Phase 4 | Status: RECRUITING